{"success":true,"data":{"pressRelease":{"id":"138337","rtpr_id":"nBw5q8vXTa-20260908","ticker":"GH","exchange":"NASDAQ","all_tickers":["GH"],"title":"Business Insider Names Guardant Health One of America's Most Innovative Businesses","author":"Business Wire","published_at":"2026-09-08T18:38:00.091Z","article_body":"Business Insider Names Guardant Health One of America's Most Innovative\nBusinesses\n\n\n * Earning the highest five-star recognition alongside only 12 other companies in\nthe biotechnology category\n\n * Recognition underscores Guardant’s leadership in precision oncology\nincluding patient growth and years of sustained R&D investment\n\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company,\ntoday announced it has been named to Business Insider’s America's Most\nInnovative Businesses 2027 list, earning the highest rating available with a\nfive-star recognition awarded to only other 12 biotechnology research\ncompanies in the category.\n\nThe inaugural Business Insider list recognizes companies for their innovative\nperformance over the preceding five years, positioning Guardant among a select\ngroup of biotechnology leaders distinguished for translating sustained\ninvestment and research output into real-world impact. The methodology focused\non three main criteria including: strong R&D investment comparable to\nrevenue, peer-to-peer perception based on a survey of industry professionals\nand patent growth and volume.\n\nAt the core of Guardant's innovation is an unparalleled infrastructure that\nincludes continuously evolving products and services, unmatched clinical\nperformance, and world-class lab operations. Additionally, InfinityAI,\nGuardant’s AI-enabled multiomic technology platform for developing and\npowering its next generation of cancer tests, drives real-world evidence for\nbiopharmaceutical research and regulatory decision-making.\n\n“We are humbled by this honor that not only reflects our continued\nleadership in comprehensive molecular profiling through liquid biopsy but\nacknowledges the rapid growth in this market and where Guardant Health is\nheaded,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “The\npower and clinical utility of our oncology portfolio, including the recently\nlaunched Guardant360® Liquid CDx that integrates genomic and epigenomic\ninsights to help clinicians make better-informed treatment selection\ndecisions, increases exponentially through the integration of our smart\nplatform and unlocks new opportunities to transform cancer care.\"\n\n\"Today's recognition reflects our commitment to making cancer detection\neasier, more accessible and more actionable,\" said AmirAli Talasaz, Guardant\nHealth co-CEO. \"For more than a decade, Guardant has pioneered blood-based\ntesting, a foundation that has grown to support over 1 million patient tests\nand counting. Over the past five years, we've scaled that expertise to bring\nShield to market: establishing the most clinically-validated screening test\nproven to double screening completion in the real-world. We’re committed to\nbuilding this momentum to ensure the latest innovations continue to reach more\npatients and become further integrated into routine care.”\n\nThe Business Insider recognition follows significant milestones for Guardant\nover the last 5 years, most notably:\n\n\n * Delivering 1 million patient tests and serving as the only cancer liquid\nbiopsy company with offerings spanning the cancer continuum.\n\n * Building one of the world’s largest blood-based data engines powered by AI\nto further improve the company’s technology platform that generates\nunmatched clinical insights through continuous learning from every patient\nsample to enhance perspective detection and expand comprehensive application.\n\n * A series of first-in-class approvals including Shield™, the leading\nFDA-approved blood test for primary colorectal cancer screening, and\nGuardant360 Liquid CDx, the largest FDA-approved liquid biopsy panel that\nassesses a 100X wider genomic footprint than the previously approved\nGuardant360 CDx.\n\n * The launch and continued commercial adoption of Shield, with a majority of\nscreening-eligible Americans now covered, marking one of the most successful\ndiagnostic launches in history outside of the COVID-19 pandemic\n\n * 29 companion diagnostic approvals for Guardant360 CDx that matches patients\nwith the best treatment regimen including the first and only FDA-approved\ndiagnostic for ESR1 in breast cancer proven to reduce disease progression and\ndeath by 56%.\n\n * Expansion of Guardant Reveal into late-stage therapy response monitoring,\nmaking it one of the fastest growing MRD tests and only clinically-validated\ntissue-free test on the market.\n\n * Launching Shield Multi-Cancer Detection (MCD) in Asia to further expand\nGuardant’s global presence and commercial access globally alongside the\ncompany’s laboratory footprint across Europe and Asia.\n\nTo learn more about Business Insider’s America’s Most Innovative\nBusinesses list, click here\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.businessinsider.com%2Famericas-most-innovative-businesses-2027-2026-8&esheet=54600402&newsitemid=20260908515275&lan=en-US&anchor=here&index=1&md5=3f884611d503c29030559ab35cbe5d2d)\n.\n\nAbout Shield\n\nShield is a methylation partitioning cell-free DNA (mp-cfDNA) non-invasive,\nblood-based screening test that detects alterations associated with colorectal\ncancer in the blood. It is intended as a screening test for individuals at\naverage risk for the disease, age 45 or older, and is not intended for\nindividuals at high risk for colorectal cancer. The Shield test can be\nconsidered in a manner similar to guideline-recommended non-invasive CRC\nscreening options and can be completed during any healthcare visit. A positive\nShield result raises concern for the presence of colorectal cancer or advanced\nadenoma and the patient should be referred for colonoscopy evaluation.\n\nAbout Guardant360® Liquid CDx\n\nThe largest FDA-approved liquid biopsy, Guardant360 Liquid CDx is the only\nFDA-approved liquid biopsy test integrating genomic and epigenomic data for\ncomprehensive insights. Guardant360 Liquid CDx is approved as a companion\ndiagnostic for multiple therapies in non-small cell lung cancer and colorectal\ncancer. It is also the only FDA-approved companion diagnostic for targeted\ntherapy in advanced breast cancer patients with ESR1 mutations. The test is\nbroadly covered by Medicare and commercial insurers, representing over 300\nmillion lives.\n\nAbout Guardant360 Liquid\n\nGuardant360 Liquid is a blood-based test that analyzes tumor DNA fragments\ncirculating in the blood (cfDNA) to identify genetic mutations in advanced\nsolid tumors, helping oncologists find targeted therapies. It offers an\nalternative to tissue biopsies, providing comprehensive genomic profiling\n(CGP) to guide personalized treatment for a wide range of solid cancers\nincluding lung, breast, colorectal, and prostate cancer. Guardant360 Liquid is\nguideline-complete across all advanced solid tumors and has been clinically\nvalidated in more than 1,500 publications and research abstracts.\n\nAbout Guardant360® CDx\n\nGuardant360 CDx is the first FDA-approved liquid biopsy for comprehensive\ngenomic profiling. It detects multiple genomic alterations across all solid\ntumors and is approved as a companion diagnostic for therapies in non-small\ncell lung cancer, breast cancer, and colorectal cancer.\n\nAbout Guardant Reveal\n\nGuardant Reveal is a tissue-free liquid biopsy test that detects minimal\nresidual disease (MRD) and monitors recurrence in early-stage colorectal,\nbreast, and lung cancers, helping oncologists guide treatment decisions. In\naddition to MRD detection, Reveal can be used for late-stage therapy response\nmonitoring for patients with solid tumors. Guardant Reveal therapy response\nmonitoring can be initiated at any time during a patient’s treatment\njourney, offering clinicians flexibility and actionable insights.\n\nThe first clinical-validation study of pan-cancer chemotherapy monitoring\npublished in The Journal of Liquid Biopsy\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS2950195425001584&esheet=54600402&newsitemid=20260908515275&lan=en-US&anchor=The+Journal+of+Liquid+Biopsy&index=2&md5=1882c9cc13a79e9a2cea9e1205eed4b8)\nshowed that Guardant Reveal predicts long-term patient benefit up to 18 months\nearlier than standard clinical measures.\n\nAbout Guardant Health\n\nGuardant Health is a leading precision oncology company focused on guarding\nwellness and giving every person more time free from cancer. Founded in 2012,\nGuardant is transforming patient care and accelerating new cancer therapies by\nproviding critical insights into what drives disease through its advanced\nblood and tissue tests, real-world data and AI analytics. Guardant tests help\nimprove outcomes across all stages of care, including screening to find cancer\nearly, monitoring for recurrence in early-stage cancer and treatment selection\nfor patients with advanced cancer. For more information, visit\nguardanthealth.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fguardanthealth.com%2F&esheet=54600402&newsitemid=20260908515275&lan=en-US&anchor=guardanthealth.com&index=3&md5=92e56b9b7ecbda7ce1760496f622b4c4)\nand follow the company on LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fguardanthealth&esheet=54600402&newsitemid=20260908515275&lan=en-US&anchor=LinkedIn&index=4&md5=82cd7383a53dda19896044cbff4aad84)\n, X (Twitter)\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2FGuardantHealth&esheet=54600402&newsitemid=20260908515275&lan=en-US&anchor=X+%28Twitter%29&index=5&md5=111e0a39571a3dbc614594e5fa373e76)\nand Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.facebook.com%2Fguardanthealth&esheet=54600402&newsitemid=20260908515275&lan=en-US&anchor=Facebook&index=6&md5=f0208c94df629147b4f63c8dd0246648)\n.\n\nAbout The Dempsey Center\n\nThe Dempsey Center was founded by actor Patrick Dempsey in 2008 after his\nmother’s experience with cancer and as a way to give back to his hometown\ncommunity of Lewiston, Maine. Today, the Dempsey Center has grown to two\nlocations in Lewiston and Westbrook, Maine, a hospitality home in Portland,\nMaine, and has adapted to providing robust support virtually via Dempsey\nConnects. Our programs provide a wide range of comprehensive supportive cancer\ncare that address the physical, functional, social, and emotional well-being\nof people impacted by cancer. All services are provided at no cost to cancer\npatients, survivors, care partners, family members, and friends. Learn more by\nvisiting DempseyCenter.org\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fdempseycenter.org&esheet=54600402&newsitemid=20260908515275&lan=en-US&anchor=DempseyCenter.org&index=7&md5=bbd29cf9ac97c85bff671e4282dac3b2)\n.\n\nGuardant Health Forward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nfederal securities laws, including statements regarding the potential\nutilities, values, benefits and advantages of Guardant Health’s liquid\nbiopsy tests or assays, which involve risks and uncertainties that could cause\nthe actual results to differ materially from the anticipated results and\nexpectations expressed in these forward-looking statements. These statements\nare based on current expectations, forecasts and assumptions, and actual\noutcomes and results could differ materially from these statements due to a\nnumber of factors. These and additional risks and uncertainties that could\naffect Guardant Health’s financial and operating results and cause actual\nresults to differ materially from those indicated by the forward-looking\nstatements made in this press release include those discussed under the\ncaptions “Risk Factors” and “Management’s Discussion and Analysis of\nFinancial Condition and Results of Operation” and elsewhere in its Annual\nReport on Form 10-K for the year ended December 31, 2025 and in its other\nreports filed with or furnished to the Securities and Exchange Commission. The\nforward-looking statements in this press release are based on information\navailable to Guardant Health as of the date hereof, and Guardant Health\ndisclaims any obligation to update any forward-looking statements provided to\nreflect any change in its expectations or any change in events, conditions, or\ncircumstances on which any such statement is based, except as required by law.\nThese forward-looking statements should not be relied upon as representing\nGuardant Health’s views as of any date subsequent to the date of this press\nrelease.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260908515275/en/\n(https://www.businesswire.com/news/home/20260908515275/en/)\n\nInvestor Contact:\n\nZarak Khurshid\n\ninvestors@guardanthealth.com \n(mailto:investors@guardanthealth.com) \n\n\nMedia Contact:\n\nMeaghan Smith\n\npress@guardanthealth.com \n(mailto:press@guardanthealth.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw5q8vXTa-20260908","title":"Business Insider Names Guardant Health One of America's Most Innovative Businesses","author":"Business Wire","ticker":"GH","created":"2026-09-08T18:38:00.091Z","tickers":["GH"],"exchange":"NASDAQ","article_body":"Business Insider Names Guardant Health One of America's Most Innovative\nBusinesses\n\n\n * Earning the highest five-star recognition alongside only 12 other companies in\nthe biotechnology category\n\n * Recognition underscores Guardant’s leadership in precision oncology\nincluding patient growth and years of sustained R&D investment\n\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company,\ntoday announced it has been named to Business Insider’s America's Most\nInnovative Businesses 2027 list, earning the highest rating available with a\nfive-star recognition awarded to only other 12 biotechnology research\ncompanies in the category.\n\nThe inaugural Business Insider list recognizes companies for their innovative\nperformance over the preceding five years, positioning Guardant among a select\ngroup of biotechnology leaders distinguished for translating sustained\ninvestment and research output into real-world impact. The methodology focused\non three main criteria including: strong R&D investment comparable to\nrevenue, peer-to-peer perception based on a survey of industry professionals\nand patent growth and volume.\n\nAt the core of Guardant's innovation is an unparalleled infrastructure that\nincludes continuously evolving products and services, unmatched clinical\nperformance, and world-class lab operations. Additionally, InfinityAI,\nGuardant’s AI-enabled multiomic technology platform for developing and\npowering its next generation of cancer tests, drives real-world evidence for\nbiopharmaceutical research and regulatory decision-making.\n\n“We are humbled by this honor that not only reflects our continued\nleadership in comprehensive molecular profiling through liquid biopsy but\nacknowledges the rapid growth in this market and where Guardant Health is\nheaded,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “The\npower and clinical utility of our oncology portfolio, including the recently\nlaunched Guardant360® Liquid CDx that integrates genomic and epigenomic\ninsights to help clinicians make better-informed treatment selection\ndecisions, increases exponentially through the integration of our smart\nplatform and unlocks new opportunities to transform cancer care.\"\n\n\"Today's recognition reflects our commitment to making cancer detection\neasier, more accessible and more actionable,\" said AmirAli Talasaz, Guardant\nHealth co-CEO. \"For more than a decade, Guardant has pioneered blood-based\ntesting, a foundation that has grown to support over 1 million patient tests\nand counting. Over the past five years, we've scaled that expertise to bring\nShield to market: establishing the most clinically-validated screening test\nproven to double screening completion in the real-world. We’re committed to\nbuilding this momentum to ensure the latest innovations continue to reach more\npatients and become further integrated into routine care.”\n\nThe Business Insider recognition follows significant milestones for Guardant\nover the last 5 years, most notably:\n\n\n * Delivering 1 million patient tests and serving as the only cancer liquid\nbiopsy company with offerings spanning the cancer continuum.\n\n * Building one of the world’s largest blood-based data engines powered by AI\nto further improve the company’s technology platform that generates\nunmatched clinical insights through continuous learning from every patient\nsample to enhance perspective detection and expand comprehensive application.\n\n * A series of first-in-class approvals including Shield™, the leading\nFDA-approved blood test for primary colorectal cancer screening, and\nGuardant360 Liquid CDx, the largest FDA-approved liquid biopsy panel that\nassesses a 100X wider genomic footprint than the previously approved\nGuardant360 CDx.\n\n * The launch and continued commercial adoption of Shield, with a majority of\nscreening-eligible Americans now covered, marking one of the most successful\ndiagnostic launches in history outside of the COVID-19 pandemic\n\n * 29 companion diagnostic approvals for Guardant360 CDx that matches patients\nwith the best treatment regimen including the first and only FDA-approved\ndiagnostic for ESR1 in breast cancer proven to reduce disease progression and\ndeath by 56%.\n\n * Expansion of Guardant Reveal into late-stage therapy response monitoring,\nmaking it one of the fastest growing MRD tests and only clinically-validated\ntissue-free test on the market.\n\n * Launching Shield Multi-Cancer Detection (MCD) in Asia to further expand\nGuardant’s global presence and commercial access globally alongside the\ncompany’s laboratory footprint across Europe and Asia.\n\nTo learn more about Business Insider’s America’s Most Innovative\nBusinesses list, click here\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.businessinsider.com%2Famericas-most-innovative-businesses-2027-2026-8&esheet=54600402&newsitemid=20260908515275&lan=en-US&anchor=here&index=1&md5=3f884611d503c29030559ab35cbe5d2d)\n.\n\nAbout Shield\n\nShield is a methylation partitioning cell-free DNA (mp-cfDNA) non-invasive,\nblood-based screening test that detects alterations associated with colorectal\ncancer in the blood. It is intended as a screening test for individuals at\naverage risk for the disease, age 45 or older, and is not intended for\nindividuals at high risk for colorectal cancer. The Shield test can be\nconsidered in a manner similar to guideline-recommended non-invasive CRC\nscreening options and can be completed during any healthcare visit. A positive\nShield result raises concern for the presence of colorectal cancer or advanced\nadenoma and the patient should be referred for colonoscopy evaluation.\n\nAbout Guardant360® Liquid CDx\n\nThe largest FDA-approved liquid biopsy, Guardant360 Liquid CDx is the only\nFDA-approved liquid biopsy test integrating genomic and epigenomic data for\ncomprehensive insights. Guardant360 Liquid CDx is approved as a companion\ndiagnostic for multiple therapies in non-small cell lung cancer and colorectal\ncancer. It is also the only FDA-approved companion diagnostic for targeted\ntherapy in advanced breast cancer patients with ESR1 mutations. The test is\nbroadly covered by Medicare and commercial insurers, representing over 300\nmillion lives.\n\nAbout Guardant360 Liquid\n\nGuardant360 Liquid is a blood-based test that analyzes tumor DNA fragments\ncirculating in the blood (cfDNA) to identify genetic mutations in advanced\nsolid tumors, helping oncologists find targeted therapies. It offers an\nalternative to tissue biopsies, providing comprehensive genomic profiling\n(CGP) to guide personalized treatment for a wide range of solid cancers\nincluding lung, breast, colorectal, and prostate cancer. Guardant360 Liquid is\nguideline-complete across all advanced solid tumors and has been clinically\nvalidated in more than 1,500 publications and research abstracts.\n\nAbout Guardant360® CDx\n\nGuardant360 CDx is the first FDA-approved liquid biopsy for comprehensive\ngenomic profiling. It detects multiple genomic alterations across all solid\ntumors and is approved as a companion diagnostic for therapies in non-small\ncell lung cancer, breast cancer, and colorectal cancer.\n\nAbout Guardant Reveal\n\nGuardant Reveal is a tissue-free liquid biopsy test that detects minimal\nresidual disease (MRD) and monitors recurrence in early-stage colorectal,\nbreast, and lung cancers, helping oncologists guide treatment decisions. In\naddition to MRD detection, Reveal can be used for late-stage therapy response\nmonitoring for patients with solid tumors. Guardant Reveal therapy response\nmonitoring can be initiated at any time during a patient’s treatment\njourney, offering clinicians flexibility and actionable insights.\n\nThe first clinical-validation study of pan-cancer chemotherapy monitoring\npublished in The Journal of Liquid Biopsy\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS2950195425001584&esheet=54600402&newsitemid=20260908515275&lan=en-US&anchor=The+Journal+of+Liquid+Biopsy&index=2&md5=1882c9cc13a79e9a2cea9e1205eed4b8)\nshowed that Guardant Reveal predicts long-term patient benefit up to 18 months\nearlier than standard clinical measures.\n\nAbout Guardant Health\n\nGuardant Health is a leading precision oncology company focused on guarding\nwellness and giving every person more time free from cancer. Founded in 2012,\nGuardant is transforming patient care and accelerating new cancer therapies by\nproviding critical insights into what drives disease through its advanced\nblood and tissue tests, real-world data and AI analytics. Guardant tests help\nimprove outcomes across all stages of care, including screening to find cancer\nearly, monitoring for recurrence in early-stage cancer and treatment selection\nfor patients with advanced cancer. For more information, visit\nguardanthealth.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fguardanthealth.com%2F&esheet=54600402&newsitemid=20260908515275&lan=en-US&anchor=guardanthealth.com&index=3&md5=92e56b9b7ecbda7ce1760496f622b4c4)\nand follow the company on LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fguardanthealth&esheet=54600402&newsitemid=20260908515275&lan=en-US&anchor=LinkedIn&index=4&md5=82cd7383a53dda19896044cbff4aad84)\n, X (Twitter)\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2FGuardantHealth&esheet=54600402&newsitemid=20260908515275&lan=en-US&anchor=X+%28Twitter%29&index=5&md5=111e0a39571a3dbc614594e5fa373e76)\nand Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.facebook.com%2Fguardanthealth&esheet=54600402&newsitemid=20260908515275&lan=en-US&anchor=Facebook&index=6&md5=f0208c94df629147b4f63c8dd0246648)\n.\n\nAbout The Dempsey Center\n\nThe Dempsey Center was founded by actor Patrick Dempsey in 2008 after his\nmother’s experience with cancer and as a way to give back to his hometown\ncommunity of Lewiston, Maine. Today, the Dempsey Center has grown to two\nlocations in Lewiston and Westbrook, Maine, a hospitality home in Portland,\nMaine, and has adapted to providing robust support virtually via Dempsey\nConnects. Our programs provide a wide range of comprehensive supportive cancer\ncare that address the physical, functional, social, and emotional well-being\nof people impacted by cancer. All services are provided at no cost to cancer\npatients, survivors, care partners, family members, and friends. Learn more by\nvisiting DempseyCenter.org\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fdempseycenter.org&esheet=54600402&newsitemid=20260908515275&lan=en-US&anchor=DempseyCenter.org&index=7&md5=bbd29cf9ac97c85bff671e4282dac3b2)\n.\n\nGuardant Health Forward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nfederal securities laws, including statements regarding the potential\nutilities, values, benefits and advantages of Guardant Health’s liquid\nbiopsy tests or assays, which involve risks and uncertainties that could cause\nthe actual results to differ materially from the anticipated results and\nexpectations expressed in these forward-looking statements. These statements\nare based on current expectations, forecasts and assumptions, and actual\noutcomes and results could differ materially from these statements due to a\nnumber of factors. These and additional risks and uncertainties that could\naffect Guardant Health’s financial and operating results and cause actual\nresults to differ materially from those indicated by the forward-looking\nstatements made in this press release include those discussed under the\ncaptions “Risk Factors” and “Management’s Discussion and Analysis of\nFinancial Condition and Results of Operation” and elsewhere in its Annual\nReport on Form 10-K for the year ended December 31, 2025 and in its other\nreports filed with or furnished to the Securities and Exchange Commission. The\nforward-looking statements in this press release are based on information\navailable to Guardant Health as of the date hereof, and Guardant Health\ndisclaims any obligation to update any forward-looking statements provided to\nreflect any change in its expectations or any change in events, conditions, or\ncircumstances on which any such statement is based, except as required by law.\nThese forward-looking statements should not be relied upon as representing\nGuardant Health’s views as of any date subsequent to the date of this press\nrelease.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260908515275/en/\n(https://www.businesswire.com/news/home/20260908515275/en/)\n\nInvestor Contact:\n\nZarak Khurshid\n\ninvestors@guardanthealth.com \n(mailto:investors@guardanthealth.com) \n\n\nMedia Contact:\n\nMeaghan Smith\n\npress@guardanthealth.com \n(mailto:press@guardanthealth.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-08T18:38:00.137877428Z","server_sent_at_ms":1788892680137},"received_at":"2026-09-08T18:38:00.194Z","source_url":"https://www.businesswire.com/news/home/20260908515275/en/"},"analysis":{"id":"127196","press_release_id":"138337","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Guardant Health has been named to Business Insider’s America's Most Innovative Businesses 2027 list, earning a five-star rating in the biotechnology category.\n\nThe recognition highlights the company's leadership in precision oncology and its sustained R&D investment, including the delivery of over 1 million patient tests.\n\nThe accolade underscores Guardant's market position and the clinical utility of its portfolio, such as Shield and Guardant360 Liquid CDx.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Five-star recognition from Business Insider validates Guardant's leadership in precision oncology and its sustained R&D investment."},"keyFigures":{"customDimensions":{"patient_tests":1000000,"companion_diagnostic_approvals":29}},"quotedText":"We are humbled by this honor that not only reflects our continued leadership in comprehensive molecular profiling through liquid biopsy but acknowledges the rapid growth in this market and where Guardant Health is headed","namedEntities":{"people":[{"name":"Helmy Eltoukhy","role":"Chairman and co-CEO"},{"name":"AmirAli Talasaz","role":"co-CEO"}],"products":["Guardant360 Liquid CDx","Shield","Shield Multi-Cancer Detection (MCD)","Guardant Reveal","InfinityAI"],"companies":[{"name":"Guardant Health, Inc.","ticker":"GH"},{"name":"Business Insider","relationship":"awarding body"},{"name":"The Dempsey Center","relationship":"partner/charity"}],"dollarAmounts":[{"amount":"over 1 million patient tests","context":"cumulative patient tests"}]},"materialImpact":{"score":2,"reasoning":"Recognition as one of America's Most Innovative Businesses is a positive brand and market validation signal, but it is a non-financial, qualitative accolade with no direct revenue or earnings impact."},"tickerRelevance":{"others":[],"primary":"GH"},"globalImportance":25,"audienceRelevance":60,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"industry_recognition","sectorWeight":"healthcare","brandValidation":true}},"event_type":"other","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Guardant Health has been named to Business Insider’s America's Most Innovative Businesses 2027 list, earning a five-star rating in the biotechnology category.\n\nThe recognition highlights the company's leadership in precision oncology and its sustained R&D investment, including the delivery of over 1 million patient tests.\n\nThe accolade underscores Guardant's market position and the clinical utility of its portfolio, such as Shield and Guardant360 Liquid CDx.","key_figures":{"customDimensions":{"patient_tests":1000000,"companion_diagnostic_approvals":29}},"named_entities":{"people":[{"name":"Helmy Eltoukhy","role":"Chairman and co-CEO"},{"name":"AmirAli Talasaz","role":"co-CEO"}],"products":["Guardant360 Liquid CDx","Shield","Shield Multi-Cancer Detection (MCD)","Guardant Reveal","InfinityAI"],"companies":[{"name":"Guardant Health, Inc.","ticker":"GH"},{"name":"Business Insider","relationship":"awarding body"},{"name":"The Dempsey Center","relationship":"partner/charity"}],"dollarAmounts":[{"amount":"over 1 million patient tests","context":"cumulative patient tests"}]},"model_name":"glm-4.7-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-08T18:39:03.047Z","global_importance":25,"audience_relevance":60,"importance_components":{"tickerTier":"mid-cap","eventGravity":"industry_recognition","sectorWeight":"healthcare","brandValidation":true}},"durationMs":62841,"modelName":"glm-4.7-flashx"}}